A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Clinical Pharmacokinetics|2017Cited by 158
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus MonkeysWouter Korver, Eric R. Fedyk, Mary Carsillo et al.|Journal of Pharmacology and Experimental Therapeutics|2019Cited by 31
Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrinA. Parikh, Irving H. Fox, Eric R. Fedyk et al.|Inflammatory Bowel Diseases|2008Cited by 4
No association between vedolizumab exposure and serum JC virus levels.A. Parikh, Catherine Milch, Eric R. Fedyk et al.|Inflammatory Bowel Diseases|2011Cited by 4
P130 - Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α 4β 7 integrinA. Parikh, Irving H. Fox, Eric R. Fedyk et al.|Journal of Crohn s and Colitis|2009Cited by 1